Abridging molecular system network of COVID-19 and thrombosis

ABSTRACT

Background: The advance pathology of SARS-CoV- 2 infection entails engagement of blood related ailment including thrombosis as secondary clinical manifestation. SARS-CoV- 2- Human protein-protein interactome has been explored. Dysregulation of the several proteins and mutations in the genes have been linked with the incidence and progression of thrombosis. Aim(s) Aim of the investigation is to develop and functionally analyze a combine molecular network of SARS-CoV- 2- Human and Thrombosis to delineate candidate molecule that could later be used for the prognosis and therapeutic intervention. Method(s) Briefly, two separate system networks were developed, one for over 500 humans protein that have shown to interact with the viral genome and 26 different proteins encoded by SARS-CoV- 2 genome. The second network is based on the genes tagged for being aberrated genetically and/or in terms of expression in thrombosis. Both networks were combined as a singular entity after removing the redundant repetition and orphans' nodes and edges by selective enrichment. The network then be dissected in different modules primarily based on the promiscuity of the nodes. Complete network and each module were assessed for in betweenness and shortest path length of edges. Result(s) The data shown over 700 genes could be coalesced as a single network providing a molecular interplay that may underpin SARS-CoV- 2 associated thrombosis. Over 16 modules were observed in the network with important candidate genes of thrombosis have been identified as hub due to the inter modular abridging potential. Identification of hub genes was further substantiated with the pathlength distance, lack of orphan edges and partner protein promiscuity. Biological functions and KEGG analysis of the holistic network and modular compartment further strengthen the predicted candidate gene status as central to the disease biology. Conclusion(s) Candidate genes identified in the study could later be used as markers for prognosis of the pathology of COVID-19 for thrombosis and/or developing therapeutic intervention.